Evidence map›Paper›PMID 30837591›Full record

ArticleScientific reports2019

An agonist antibody prefers relapsed AML for induction of cells that kill each other.

Kyungmoo Yea, Teresa M Jones, Dokyung Jung, Sanghee Shin, Britni M Arlian, Kyung Ho Han, Zhao Zha, Minseok S Kim, Yong-Seok Oh, Hongkai Zhang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Kyungmoo YeaDepartment of New Biology, DGIST, Daegu, 42988, Republic of Korea.
Teresa M JonesDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Dokyung JungDepartment of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Sanghee ShinDepartment of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Britni M ArlianDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Kyung Ho HanDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Zhao ZhaDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Minseok S KimDepartment of New Biology, DGIST, Daegu, 42988, Republic of Korea.ORCID 0000-0002-4268-6886
Yong-Seok OhDepartment of Brain-Cognitive Science, DGIST, Daegu, 42988, Republic of Korea.ORCID 0000-0002-9039-2014
Hongkai ZhangState Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, China.
Richard A LernerDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA. rlerner@scripps.edu.
Scripps Research Institute · USDaegu Gyeongbuk Institute of Science and Technology · KRKyungpook National University · KRNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we reported an agonist antibody to a cytokine receptor, Thrombopoietin receptor (TPOR) that effectively induces cytotoxic killer cells from precursor tumor cells isolated from newly diagnosed AML patients. Here, we show that the TPOR agonist antibody can induce even relapsed AML cells into killer cells more potently than newly diagnosed AML cells. After stimulation by the agonist antibody, these relapsed leukemic cells enter into a differentiation process of killer cells. The antibody-induced killer cells express, Granzyme B and Perforin that assault and kill other members of the AML cell population. Particularly, the agonist antibody showed potent efficacy on the AML xenograft model in mice using the NOD/LtSz-scid IL2Rγc null (NSG) mice. These results show that the TPOR agonist antibody that induces AML cells to kill each other is effective on both relapsed AML cells and in vivo. Therefore, this study suggests a new strategy for the treatment of cancer relapse after chemotherapy.

Indexed as

AnimalsAntibodiesCell Line, TumorHumansKiller Cells, NaturalLeukemia, Myeloid, AcuteMiceMice, Inbred NODMice, SCIDReceptors, ThrombopoietinRecombinant ProteinsRecurrenceSignal TransductionThrombopoietinTransplantation, HeterologousAntibodiesReceptors, ThrombopoietinRecombinant ProteinsThrombopoietin

Identifiers

PMID30837591
PMCPMC6401169
OpenAlexW2920310246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.